NCT06119789 Precision Cancer Therapy in Rare Cancers
| NCT ID | NCT06119789 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Oslo University Hospital |
| Condition | Rare Malignant Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2025-03-20 |
| Primary Completion | 2033-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 96 participants in total. It began in 2025-03-20 with a primary completion date of 2033-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Eligibility Criteria
Inclusion Criteria: * ECOG 0-2, * identified biomarker, * reasonable biochemistry Exclusion Criteria: * ECOG 3-5 * serious other diseases
Contact & Investigator
Sigbjørn Smeland, MD PhD
STUDY CHAIR
Oslo University Hospital
Frequently Asked Questions
Who can join the NCT06119789 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 99 Years, studying Rare Malignant Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06119789 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06119789 currently recruiting?
Yes, NCT06119789 is actively recruiting participants. Contact the research team at ahelland@medisin.uio.no for enrollment information.
Where is the NCT06119789 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT06119789 clinical trial?
NCT06119789 is sponsored by Oslo University Hospital. The principal investigator is Sigbjørn Smeland, MD PhD at Oslo University Hospital. The trial plans to enroll 96 participants.